NCT06406348

A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants

A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Single Ascending Dose Trial to Assess the Safety, Tolerability and Pharmacokinetic Effects of ALIA-1758 in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

This is a Phase 1, first in human (FIH), double-blind, placebo-controlled, single ascending dose (SAD) trial to assess the safety, tolerability, and pharmacokinetics (PK) of intravenously (IV) or subcutaneously (SC) injected ALIA-1758 in healthy male and female participants.

Conditions

• Alzheimer Disease

Interventions

Type	Name	Description
DRUG	ALIA-1758	Intravenous or subcutaneous doses
OTHER	Placebo	Intravenous or subcutaneous doses

Timeline

• Start date: 2024-05-09
• Primary completion: 2025-04-22
• Completion: 2025-04-22
• First posted: 2024-05-09
• Last updated: 2025-07-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study